The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized phase I/II study of neoadjuvant treatment with 177-Lutetium-PSMA-617 with or without ipilimumab in patients with very high-risk prostate cancer who are candidates for radical prostatectomy (NEPI trial).
 
Ulrich Krafft
Honoraria - Klinikverbund
Research Funding - Bristol Myers Squibb Foundation (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Intuitive Surgical; Klinikverbund
 
Viktor Grünwald
Employment - University Hospital Essen
Stock and Other Ownership Interests - AstraZeneca; Bristol-Myers Squibb; Genmab; MSD; Seagen
Honoraria - Advanced Accelerator Applications/Novartis; Amgen; Apogepha; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Janssen-Cilag; Merck Serono; MSD Oncology; Nanobiotix; Ono Pharmaceutical; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb; Cor2Ed; Cureteq; Debiopharm Group; Eisai; Gilead Sciences; Ipsen; Janssen-Cilag; MSD Oncology; Novartis; Oncorena; Onkowissen; PCI Biotech; Pfizer; Synthekine
Research Funding - Amgen (Inst); BMS (Inst); Gilead Sciences (Inst); Ipsen (Inst); MSD Oncology (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Janssen; Merck Serono; Pfizer
 
Wolfgang P. Fendler
Honoraria - Parexel
Consulting or Advisory Role - Calyx; Janssen
Speakers' Bureau - ABX Advanced biochemical compounds; Amgen; Bayer; Eczacibasi Monrol; GE Healthcare; Janssen; Novartis; Telix Pharmaceuticals
Research Funding - SOFIE
 
Ken Herrmann
Leadership - Pharma15; SOFIE; Theragnostics
Stock and Other Ownership Interests - AdvanCell; Aktis Oncology; Convergent Therapeutics; Pharma15; SOFIE; Theragnostics
Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; AstraZeneca; Bain Capital; Bayer; Boston Scientific; BTG; Debiopharm Group; Fusion Pharmaceuticals; GE Healthcare; Immedica; IPSEN; ITG (Inst); Janssen Oncology; Molecular Partners; Novartis; Radiopharm Theranostics; ROTOP Pharmaka (Inst); Siemens Healthineers; Telix Pharmaceuticals
 
Henning Reis
Stock and Other Ownership Interests - Bayer
Honoraria - BMS GmbH & Co. KG; Boehringer Ingelheim; Comprehensive Haematology and Oncology Practice (CHOP); Diaceutics; GlaxoSmithKline; Janssen; MCI Deutschland; Merck; Novartis; Roche; Sanofi
Consulting or Advisory Role - BMS GmbH & Co. KG; Roche
Research Funding - BMS GmbH & Co. KG
Travel, Accommodations, Expenses - BMS GmbH & Co. KG; Philips Electronics; Roche
 
Florian Roghmann
No Relationships to Disclose
 
Kambiz Rahbar
Honoraria - ABX Advanced biochemical compounds; AstraZeneca; Bayer; Novartis
Travel, Accommodations, Expenses - Bayer
 
Axel Heidenreich
Honoraria - Amgen; Astellas Pharma; Bayer; Ferring; Ipsen; Janssen-Cilag; Sanofi; Takeda
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; BMS Global; Clovis Oncology; Janssen-Cilag; MSD Oncology
Speakers' Bureau - Amgen; Astellas Pharma; Bayer; Ipsen; Johnson & Johnson; Pfizer; Sanofi; Takeda
Research Funding - Astellas Pharma; Bayer; BMS Oncology; Sanofi
 
Frederik Giesel
No Relationships to Disclose
 
Guenter Niegisch
Honoraria - Astellas Pharma; AstraZeneca; Medac; Pfizer; Roche Pharma AG
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Janssen Oncology; Merck/Pfizer; Pfizer; Roche Pharma AG
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Celgene; Merck; Roche Pharma AG
 
Boris A. Hadaschik
Consulting or Advisory Role - ABX Advanced biochemical compounds; Accord Healthcare; Amgen; Astellas Pharma; Bayer; BMS GmbH & Co. KG; Ipsen; Janssen; Lightpoint medical; Merck KGaA; MSD; Novartis; Onkowissen; Pfizer; POINT Biopharma
Research Funding - Bristol Myers Squibb (Inst); Janssen; Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Uromed
Travel, Accommodations, Expenses - AstraZeneca; Bayer; BMS; Ipsen; Janssen